Ivy Natal

Ivy Natal develops advanced fertility solutions using a proprietary cellular engineering platform that transforms normal cells into reproductive cells, addressing infertility challenges and enhancing animal agriculture. Founded in 2020 in San Francisco, US, Ivy Natal specializes in innovative fertility technologies. The company was co-founded by Colin Bortner and Jeffrey Hsu, who both hold the CEO position. Ivy Natal has completed two deals, with its most recent funding round taking place on April 14, 2020, during which it raised an undisclosed amount of Seed funding from IndieBio and SOSV.

Ivy Natal specializes in next-generation fertility solutions by utilizing its proprietary cellular engineering platform to convert normal cells into reproductive cells. This innovative approach aims to address infertility challenges while also contributing to advancements in animal agriculture. The company's core product offerings include engineered reproductive cells designed for both human fertility treatments and agricultural applications, targeting a broad spectrum of end users, including fertility clinics, healthcare providers, and agricultural businesses. Ivy Natal’s products are designed to enhance the efficiency and success rates of reproductive procedures, ultimately catering to individuals facing infertility and agricultural entities seeking to improve livestock reproduction rates.

The geographical markets for Ivy Natal’s offerings include North America and select regions in Europe, where both human fertility and agricultural issues are prevalent. Ivy Natal generates revenue through a combination of direct partnerships with fertility clinics and agricultural organizations, as well as potential licensing agreements for its advanced cellular technologies. The business model primarily focuses on B2B transactions, where the company collaborates with healthcare providers and agricultural firms to integrate its engineered reproductive cells into their existing systems. This collaborative framework allows for tailored solutions to specific challenges in fertility and agriculture, with transactions structured around project-based contracts and ongoing service agreements.

Pricing plans for Ivy Natal’s offerings are determined based on the specific needs and scales of their clients, reflecting the customizable nature of their products and services. The flagship offerings, which center on engineered reproductive cells, form the core of the company's revenue strategy, addressing the critical demand for innovative fertility solutions in both human and animal sectors. Ivy Natal is focused on expanding its product line and market presence. It is working on designing new engineered reproductive solutions targeted for release in 2023.

The company plans to expand its geographical reach into additional regions across Europe and Asia by the end of 2024. The recent Seed funding raised in April 2020 will be utilized to support these initiatives, enhancing their R&D capabilities and facilitating market entry efforts.